Literature DB >> 15155149

Psychotic symptoms in Parkinson's disease: pathophysiology and management.

J L W Bosboom1, E Ch Wolters.   

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disease, in which mainly dopaminergic neurons in the substantia nigra in the brain degenerate, leading to a depletion of dopamine (DA) in the striatum. The most important motor disturbances of the disease are bradykinesia (slowing down of movement), hypokinesia (poverty of movement), rigidity (muscle stiffness), tremor and postural instability. Besides these well-known motor symptoms, non-motor symptoms may develop, such as depression, cognitive impairment and psychosis. Psychotic symptoms constitute a relatively common but nevertheless serious complication, with visual hallucinations and paranoid delusions often being most prominent. These symptoms are important contributors to patient and caregiver distress and are often important risk factors for nursing home placement. Exogenous (related to therapeutic interventions) factors are of major importance but endogenous (related to the disease process itself) factors might also contribute to the development of psychotic symptoms in PD. Therapeutic strategies comprise reduction of antiparkinsonian treatment, cholinesterase inhibitors and atypical antipsychotics. As psychotic symptoms in PD are often influenced by both endogenous and exogenous factors, a combination of strategies may be chosen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155149     DOI: 10.1517/eods.3.3.209.31071

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  3 in total

1.  Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Authors:  Amal Alachkar; Jonathan M Brotchie; Owen T Jones
Journal:  J Mol Neurosci       Date:  2011-05-12       Impact factor: 3.444

2.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

3.  Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan.

Authors:  I-Hsun Li; Senyeong Kao; Hsiu-Feng Wu; Li-Ting Kao; Jui-Hu Shih; Hui-Han Kao; Yu-Ching Chou
Journal:  BMJ Open       Date:  2018-08-29       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.